Risk adjusted net present value: What is the current valuation of Vigil Neuroscience’s Iluzanebart?

Iluzanebart is a monoclonal antibody commercialized by Vigil Neuroscience, with a leading Phase III program in Neurodegenerative Diseases.

The Ozempic panic: Why a market frenzy over new weight loss drugs defies logic

There’s a specter haunting Wall Street. It started in biotech, where companies making drugs for the obesity-related liver disease NASH saw their valuations crash on

October 18, 2023

Ten biotech executives who reaped the biggest M&A windfalls, netting $40M+ exit packages

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

July 12, 2024

One Doctor’s Compound Interest Scorecard

When I first learned how to calculate my net worth, one concept struck me: I was in a battle with and against compound interest. Furthermore,

June 28, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.